Search results

  1. In those patients with a new diagnosis of hypertension or type 2 diabetes aged 25-84 years, recorded between the preceding 1 April to 31 March (excluding those with pre-existing CHD, stroke and/or TIA), who have a recorded CVD risk assessment score (using the QRISK2 assessment tool) of more than 20% in the preceding 12 months: the percentage who are currently treated with statins (unless there is a contraindication)

    In those patients with a new diagnosis of hypertension or type 2 diabetes aged 25-84 years, recorded between the preceding 1 April to 31 March...

  2. The percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which included: assessment of stroke/VTE risk; assessment of bleeding risk; assessment of renal function, creatinine clearance, FBC and LFTs as appropriate for their anticoagulation therapy; any adverse effects related to anticoagulation; assessment of compliance; choice of anticoagulant

    The percentage of patients with atrial fibrillation, currently treated with an anticoagulant, who have had a review in the preceding 12 months which...

  3. The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or dementia with a FAST score of 3 or more or AUDIT-C score of 5 or more in the preceding 2 years who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded

    The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or...

  4. The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more)

    The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring...

  5. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    Recommendation ID NG188/2 Question What are the most clinically effective interventions (including social prescribing and structured community

  6. Evidence on the safety and efficacy of balloon cryoablation for squamous dysplasia of the oesophagus is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. This could be in the form of randomised controlled trials or published registry data.   Find out  what only in research means on the NICE interventional procedures guidance page .

    Recommendation ID IPG683/1 Question Evidence on the safety and efficacy of balloon cryoablation for squamous dysplasia of the oesophagus

  7. Evidence on the safety and efficacy of balloon cryoablation for Barrett's oesophagus is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. This could be in the form of randomised controlled trials or published registry data.   Find out  what only in research means on the NICE interventional procedures guidance page .

    Recommendation ID IPG682/1 Question Evidence on the safety and efficacy of balloon cryoablation for Barrett's oesophagus is inadequate

  8. Evidence on the safety of the swallowable gastric balloon capsule for weight loss shows infrequent but potentially serious adverse events: For people who need to lose weight in the short term for medical reasons, the evidence of efficacy is adequate to support the use of this procedure provided that special arrangements are in place for clinical governance, consent and audit.  Find out  what special arrangements mean on the NICE interventional procedures guidance page . For people who are aiming for long-term weight loss, the evidence on efficacy is inadequate in quantity and quality, so the procedure should only be used in the context of research.   Find out  what only in research means on the NICE interventional procedures guidance page .

    Recommendation ID IPG684/1 Question Evidence on the safety of the swallowable gastric balloon capsule for weight loss shows infrequent

  9. Evidence on the safety of pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis shows that this procedure can cause serious but well-recognised side effects. Evidence on its efficacy is inadequate in quality. Therefore, this procedure should only be used in the context of research. Find out what  only in research means on the NICE website .

    Recommendation ID IPG681/1 Question Evidence on the safety of pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis

  10. Develop and validate new and existing screening tools (including physical, psychological and psychiatric aspects) for post-COVID-19 syndrome in a UK population. What tools are validated for screening for post‑COVID‑19 syndrome, which are the most accurate at identifying post‑COVID‑19 syndrome in a UK population and what is their effectiveness in guiding management?

    Recommendation ID NG188/7 Question Develop and validate new and existing screening tools (including physical, psychological and